Vimarsana
Biggest News Aggregation in the World

Page 27 - Rna News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rna. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rna Today - Breaking & Trending Today

Assessing the Promise of AI in Oncology: Matching Patients With Clinical Trials - Vimarsana News

Assessing the Promise of AI in Oncology: Matching Patients With Clinical Trials

In this eighth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain how artificial intelligence tools are being developed to match the right patient to the right drug on the right clinical trial.

FDA responds to Ladapo letter | Blaze Media - Vimarsana News

FDA responds to Ladapo letter | Blaze Media

In response to a letter in which Florida Surgeon General Joseph Ladapo noted the detection of DNA fragments in mRNA COVID-19 vaccines, Peter Marks, director of the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research, emphasized the FDA's view that the shots are safe and effective.

COVID mRNA vaccines required no safety oversight | Eastern North Carolina Now - Vimarsana News

COVID mRNA vaccines required no safety oversight | Eastern North Carolina Now

Look into the process of COVID mRNA shot approval

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by Mirador Capital Partners LP - Vimarsana News

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by Mirador Capital Partners LP

Mirador Capital Partners LP decreased its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 76.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,366 shares of the biotechnology company’s stock after selling 53,395 shares during the period. Mirador Capital […]

Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology - Vimarsana News

Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology

BARCELONA, Spain & NIEL, Belgium, December 12, 2023--Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced today a multi-target alliance to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.

Source: yahoo.com